100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.


Read more
  • 0

BioMarin lays off 120 employees in effort to “better focus”

BioMarin Pharmaceutical (Nasdaq:BMRN) saw its share price dip 3.5% in mid-day trading to $88.30 after announcing a reorganization.

The company said it would cut 4% of its workforce, or approximately 120 positions, to save cash.

In a press release, BioMarin cited the potential launch of Roctavian as one of the reasons beyond the layoff. The company also said the reorganization would enable it to “better focus” on its R&D pipeline and capitalize on commercial launches.

“Change is necessary to fulfill our commitment to operating the business in the best interest of our patients, shareholders, and other stakeholders. This requires that our organization is the right size, has the right structure, and has the right focus to operate with maximum effectiveness and efficiency,” said Jean-Jacques Bienaimé, CEO of BioMarin, in a news release. “This change allows us to continue building upon our core strength in genetic discovery to…

Read more
  • 0